671 related articles for article (PubMed ID: 27902939)
1. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
[TBL] [Abstract][Full Text] [Related]
2. Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit.
Tahlan A; Ahluwalia J
Arch Pathol Lab Med; 2014 Feb; 138(2):278-81. PubMed ID: 24476525
[TBL] [Abstract][Full Text] [Related]
3. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
[TBL] [Abstract][Full Text] [Related]
5. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions.
Dickneite G; Herwald H; Korte W; Allanore Y; Denton CP; Matucci Cerinic M
Thromb Haemost; 2015 Apr; 113(4):686-97. PubMed ID: 25652913
[TBL] [Abstract][Full Text] [Related]
6. Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
Carcao M; Fukutake K; Inbal A; Kerlin B; Lassila R; Oldenburg J; Garly ML; Nugent D
Semin Thromb Hemost; 2017 Feb; 43(1):59-68. PubMed ID: 27556350
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
[TBL] [Abstract][Full Text] [Related]
8. Clinical Use of Factor XIII Concentrates.
Lassila R
Semin Thromb Hemost; 2016 Jun; 42(4):440-4. PubMed ID: 27071044
[TBL] [Abstract][Full Text] [Related]
9. Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
Duval C; Ali M; Chaudhry WW; Ridger VC; Ariëns RA; Philippou H
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):308-16. PubMed ID: 26743168
[TBL] [Abstract][Full Text] [Related]
10. The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking.
Souri M; Osaki T; Ichinose A
J Biol Chem; 2015 May; 290(19):12027-39. PubMed ID: 25809477
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
[TBL] [Abstract][Full Text] [Related]
12. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
[TBL] [Abstract][Full Text] [Related]
14. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.
Souri M; Koseki-Kuno S; Takeda N; Degen JL; Ichinose A
Int J Hematol; 2008 Jan; 87(1):60-8. PubMed ID: 18224415
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
[TBL] [Abstract][Full Text] [Related]
16. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Standeven KF; Ariëns RA; Whitaker P; Ashcroft AE; Weisel JW; Grant PJ
Diabetes; 2002 Jan; 51(1):189-97. PubMed ID: 11756340
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.
Reynolds TC; Butine MD; Visich JE; Gunewardena KA; MacMahon M; Pederson S; Bishop PD; Morton KM
J Thromb Haemost; 2005 May; 3(5):922-8. PubMed ID: 15869585
[TBL] [Abstract][Full Text] [Related]
18. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.
Al-Khabori M; Pathare A; Menegatti M; Peyvandi F
J Thromb Haemost; 2018 Jun; 16(6):1052-1054. PubMed ID: 29665207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
